Search

everythinglearnresearchcommunity

for

Search:↓

Shedding after two months of using 1.5 mg finasteride is a common concern. It's often a normal part of the hair growth cycle.

User shared a 2-year progress update on hair regrowth using 1mg finasteride and 2.5mg oral minoxidil daily. They switched from topical to oral minoxidil for ease of use and showed significant improvement.

Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.

The user has been taking dutasteride for 7 months with unimpressive results and recently started using minoxidil once a day. They are inquiring about the effectiveness of using minoxidil twice a day and the addition of tretinoin to enhance results.

Using minoxidil twice daily may offer around 20% better regrowth compared to once daily, but once daily is still effective, especially with dermastamping. The user also uses dutasteride and finasteride daily, and is considering increasing minoxidil application despite concerns about cost and potential shedding.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

The user is seeking a quicker-drying carrier for RU58841 and Minoxidil to improve adherence to their hair loss treatment routine. They want to apply it after a morning shower without affecting their hair's appearance.

A user wants to add tretinoin to their nightly minoxidil and finasteride combo to increase effectiveness. They seek advice on how to mix tretinoin with the existing treatment.

A 23-year-old is considering using a topical solution of Finjuve (finasteride and minoxidil) at a reduced dosage of 0.2/0.4mg to treat crown thinning while minimizing side effects. Applying 0.1-0.2 mL is suggested to lower systemic absorption and effectively reduce DHT on the scalp.

The post and conversation are about using RU58841 mixed with Minoxidil once a night for hair loss. The user experienced side effects from Finasteride and chose RU58841 instead.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

The conversation is about the safety of using a dermastamp at 0.25mm depth twice a day when applying Minoxidil. The user seeks confirmation on whether this practice is safe despite mixed opinions.

A 23-year-old male with early stage 4 hair loss is using a treatment routine that includes minoxidil 5% with tretinoin once daily, finasteride 1mg every other day, 2.5mg oral minoxidil every other day, and derma rolling twice a week. The discussion is about whether using minoxidil twice a day is better than combining it with tretinoin once a day.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Missing finasteride for 1-2 weeks is generally not a major issue, as it takes time for hair loss to progress. It's advised to sort out the refill for consistency, but short breaks are usually fine.

Topical liquid minoxidil may be safe to consume in small amounts, but it needs liver processing to become effective for hair growth. Therefore, oral pills might be more effective.

A user started taking 1mg of finasteride daily but experienced anxiety and brain fog, considering reducing the dose to 0.5mg to adjust. They seek advice on whether this change could help manage side effects and hair shedding.

User shared 15-month progress using Oral Dutasteride and Sublingual Minoxidil for hair loss. Treatment improved hair density, now considering hair transplant with fewer grafts.

A user's 2.5 year transformation of using 0.5mg finasteride and RU58841 to combat hair loss, with the possibility of increasing the RU for further regrowth.

Switching from 1mg finasteride to dutasteride, with users recommending starting at 0.5mg daily. Some users prefer capsules, while others use tablets, citing effectiveness and regulatory approval in Asia.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.